<DOC>
	<DOCNO>NCT00437060</DOCNO>
	<brief_summary>This clinical trial look brain function young patient receive methotrexate acute lymphoblastic leukemia . Learning long-term effect methotrexate brain function may help doctor plan cancer treatment .</brief_summary>
	<brief_title>Brain Function Young Patients Receiving Methotrexate Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine neuropsychological function child acute lymphoblastic leukemia treat either high-dose methotrexate escalating-dose methotrexate absence cranial radiation nelarabine . II . Identify host polymorphism predict increase risk neurocognitive dysfunction acute neurotoxicity patient . III . Correlate neuropsychological outcome measure occurrence acute neurotoxicity host polymorphism patient . IV . Measure concentration 5-methyltetrahydrofolate , homocysteine , Ado , S-adenosylmethionine , S-adenosylhomocysteine , potentially relevant compound serum cerebrospinal fluid interim maintenance therapy low- high-dose methotrexate regimen , respectively , correlate endpoint occurrence acute neurologic toxicity long-term neurocognitive dysfunction patient . V. Determine whether diffusion tensor image identify area selective vulnerability CNS provide image modality predict and/or correlate neuropsychological outcome . OUTLINE : This prospective , cohort , multicenter study . Patients complete neurocognitive test assess think , memory , attention , concentration . The baseline test administer consolidation phase chemotherapy test do 1 year baseline 1 year after* completion study therapy . Patients undergo blood cerebrospinal fluid collection periodically biomarker , genotypic polymorphism , pharmacokinetic analysis . Patients undergo MRI diffusion-tensor image correlate image neuropsychological outcome . NOTE : * Within 8 month 24 month completion study therapy patient AALL0232 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Diagnosis acute lymphoblastic leukemia Enrolled COGAALL0434 ( Cohort # 1 ) COGAALL0232 ( Cohorts # 1 # 2 ) Patients must receive either highdose methotrexate escalatingdose methotrexate interim maintenance . No CNS3 disease Patients must enroll within 824 month completion therapy COGAALL0232 evidence relapse secondary malignancy No known significant neurodevelopmental disability unrelated cancer diagnosis include , limited , follow : Down syndrome Fragile X mental retardation Autism Pervasive developmental disability Seizure disorder Attentiondeficit hyperactivity disorder specific learn disability ( e.g. , dyslexia ) allow No sensory impairment ( e.g. , preexist uncorrectable vision impairment deafness ) No cranial radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>